Septerna (Novel G Protein-Coupled Receptor Program) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Septerna (Novel G Protein-Coupled Receptor Program) General Information

Description

A novel G protein-coupled receptor program.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • South San Francisco, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Vertex Pharmaceuticals
Corporate Office
  • South San Francisco, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Septerna (Novel G Protein-Coupled Receptor Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Septerna (Novel G Protein-Coupled Receptor Program)‘s full profile, request access.

Request a free trial

Septerna (Novel G Protein-Coupled Receptor Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Septerna (Novel G Protein-Coupled Receptor Program)‘s full profile, request access.

Request a free trial

Septerna (Novel G Protein-Coupled Receptor Program) FAQs

  • Where is Septerna (Novel G Protein-Coupled Receptor Program) headquartered?

    Septerna (Novel G Protein-Coupled Receptor Program) is headquartered in South San Francisco, CA.

  • What industry is Septerna (Novel G Protein-Coupled Receptor Program) in?

    Septerna (Novel G Protein-Coupled Receptor Program)’s primary industry is Buildings and Property.

  • Is Septerna (Novel G Protein-Coupled Receptor Program) a private or public company?

    Septerna (Novel G Protein-Coupled Receptor Program) is a Private company.

  • What is the current valuation of Septerna (Novel G Protein-Coupled Receptor Program)?

    The current valuation of Septerna (Novel G Protein-Coupled Receptor Program) is .

  • What is Septerna (Novel G Protein-Coupled Receptor Program)’s current revenue?

    The current revenue for Septerna (Novel G Protein-Coupled Receptor Program) is .

  • Who are Septerna (Novel G Protein-Coupled Receptor Program)’s investors?

    Septerna has invested in Septerna (Novel G Protein-Coupled Receptor Program).

  • When was Septerna (Novel G Protein-Coupled Receptor Program) acquired?

    Septerna (Novel G Protein-Coupled Receptor Program) was acquired on 12-Sep-2024.

  • Who acquired Septerna (Novel G Protein-Coupled Receptor Program)?

    Septerna (Novel G Protein-Coupled Receptor Program) was acquired by Vertex Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process